Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
Endeavor Biomedicines, Inc.
Emory University
Eli Lilly and Company
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Hoffmann-La Roche
Jazz Pharmaceuticals
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Milton S. Hershey Medical Center
Novartis
Valent Technologies, LLC
Memorial Sloan Kettering Cancer Center